Kiniksa Pharmaceuticals International, plc (KNSA) stock
Close on Nov 12, 2026Market cap $15.13BP/E 74.1Yield –
Kiniksa Pharmaceuticals International, plc grew revenue 58.2% to $945.96M over the twelve months to Sep 30, 2026. Operating income rose 241.9% to $130.47M, moving the operating margin from 6.4% to 13.8%. Free cash flow was $197.20M, up 93.8% from a year earlier. At the latest close the market valued the company at $15.13B, 74.1 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $15.13B
- P/E ratio
- 74.1
- Price to sales
- 15.99
- Price to book
- 21.30
- Dividend yield
- –
- Free cash flow yield
- 1.30%
Fundamentals
- Revenue
- $945.96M
- Net income
- $109.57M
- EPS, diluted
- $1.30
- Free cash flow
- $197.20M
- Book value per share
- $8.36
- Diluted shares
- 85M
Trading
- Next earnings
- Feb 23, 2027 (estimated, before the open)
- Previous close
- $95.76
- Open
- $95.85
- Day's range
- $94.32 – $96.67
- Volume
- 368,780
- Average volume (20 days)
- 961,326
- Beta (5 years)
- 0.31
- 52-week range
- $37.02 – $99.31
- RSI (14 days)
- 60.1
- Volatility (1 year)
- 56.2%
- Relative volume
- 0.55×
- WACC
- 7.5%
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | KNSA | S&P 500 | Difference | KNSA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +21.5% | -2.7% | +24.2 pts | ||
| 3 months | +23.2% | -1.7% | +24.9 pts | ||
| Year to date | +133.4% | +11.9% | +121.5 pts | ||
| 1 year | +137.3% | +12.0% | +125.3 pts | ||
| 3 years | +566.8% | +78.2% | +488.6 pts | +88.2% | +21.2% |
| 5 years | +619.0% | +73.2% | +545.8 pts | +48.4% | +11.6% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Kiniksa Pharmaceuticals International filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio ExecutionResults
- Results
- Results
- Results
- Results
About Kiniksa Pharmaceuticals International
Pharmaceutical Preparations
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for debilitating diseases with significant unmet medical need, particularly cardiovascular and autoinflammatory conditions. Its commercial product, ARCALYST, is an interleukin-1 alpha and beta cytokine trap approved in the United States to treat recurrent pericarditis, Cryopyrin-Associated Periodic Syndromes, and Deficiency of Interleukin-1 Receptor Antagonist. The company delivers ARCALYST to patients through a network of specialty pharmacies, while advancing investigational clinical candidates such as KPL-387 for recurrent pericarditis and preclinical programs like KPL-1161.
Company profile, executives and historyKiniksa Pharmaceuticals International stock: common questions
What is Kiniksa Pharmaceuticals International's stock price?
KNSA closed at $96.28 on Nov 12, 2026, up 0.54% on the day. Over the past 52 weeks it traded between $37.02 and $99.31.
What is Kiniksa Pharmaceuticals International's market cap?
Kiniksa Pharmaceuticals International was worth $15.13B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is KNSA's P/E ratio?
KNSA trades at 74.1 times earnings, based on diluted earnings per share of $1.30 over the twelve months to Sep 30, 2026.
How much revenue does Kiniksa Pharmaceuticals International make?
Kiniksa Pharmaceuticals International reported revenue of $945.96M for the twelve months to Sep 30, 2026, up 58.2% from a year earlier.
Does Kiniksa Pharmaceuticals International pay a dividend?
No. Kiniksa Pharmaceuticals International has not paid a cash dividend over the last twelve months.
When does Kiniksa Pharmaceuticals International report earnings next?
Kiniksa Pharmaceuticals International is expected to report Q4 FY2026 results on Feb 23, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has KNSA stock performed over the past year?
Including dividends, KNSA returned +137.3% over the past year, against +12.0% for the S&P 500.
How many KNSA shares are sold short?
4M shares were sold short at the latest FINRA report, 2.88% of the float, or 3.9 days of average trading volume.
Who are Kiniksa Pharmaceuticals International's competitors?
Companies most similar to Kiniksa Pharmaceuticals International by business, industry and size include BBIO, INSM, IONS, TVTX, ARWR.
See a number that looks wrong?